The downregulation of miR-181a/b has shown therapeutic benefits in neurodegenerative disorders, including RP caused by mutations in the Rhodopsin (Rho) and Phosphodiesterase 6β (Pde6β) genes [18, 36]. Here, RHO is linked to retinitis pigmentosa 1.